革兰阳性多重耐药菌假体周围感染管理:现状与创新策略综述
本文综述了革兰阳性多重耐药菌引起假体周围感染的临床影响及治疗策略。耐甲氧西林对预后影响存争议,而利福平和/或氟喹诺酮耐药与更差预后相关,或可视为难治性病原体。新抗革兰阳性药物在假体周围感染中经验有限,但抗生物膜活性及药代动力学优势(如替地唑胺、达巴万星)具前景,局部给药、药代动力学监测、抑制性治疗及噬菌体等创新策略值得评估。
要点
- 耐甲氧西林对假体周围感染预后影响存争议,尤其凝固酶阴性葡萄球菌。
- 利福平和/或氟喹诺酮耐药与更差预后相关,或可视为难治性病原体。
- 新抗革兰阳性药物在假体周围感染中经验有限,抗生物膜活性及药代动力学优势具前景。
核心结论
- 耐利福平和/或氟喹诺酮的葡萄球菌所致假体周围感染可能与更差预后相关,需优化内外科管理并寻找新治疗选择。
研究设计与样本
- 叙述性综述,基于PubMed检索相关主题,因随机试验极少,讨论主要基于观察性研究及作者经验与观点。
主要发现
- 耐甲氧西林是葡萄球菌假体周围感染的重要关注点,尤其凝固酶阴性葡萄球菌,但其对预后的影响存争议。
- 利福平和/或氟喹诺酮耐药与更差预后相关,或可考虑用于定义假体周围感染中的难治性病原体。
- 新抗革兰阳性药物在假体周围感染中经验很少,但抗生物膜活性评估有前景,部分药物可能在长期治疗中带来显著进步(如替地唑胺的抗菌耐受性、达巴万星的药代动力学特征)。
临床怎么用
- 对耐药革兰阳性菌所致假体周围感染,需优化内科与外科管理。
- 可评估创新策略,包括利用局部抗菌药物递送重新定位现有手术选项、药代动力学监测与建模优化抗菌治疗、抑制性抗菌治疗和/或基于噬菌体的方法。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Prosthetic joint infection (PJI) is a devastating complication of arthroplasty surgery, mostly caused by Gram-positive pathogens, including Staphylococcus aureus and coagulase-negative staphylococci. Multidrug resistance is of major concern in this setting: (a) it can negatively impact outcome, restricting the use of the most effective antimicrobials; (b) it may influence the choice of surgical strategies; and (c) it restrains the therapeutic options to newly labelled antimicrobials with limited experience in PJI. OBJECTIVES: To provide a comprehensive overview of the clinical impact of antimicrobial resistance in Gram-positive PJI and on current and innovative therapeutic strategies. SOURCES: The review is based on PubMed searches for relevant topics, including multiresistant staphylococci PJI and the discussed specific therapeutic approaches. Given the very few randomized trials in this setting, discussion is mostly based on observational studies and the experience and opinion of the authors. CONTENT: Methicillin resistance is an important concern in staphylococcal PJI, especially in coagulase-negative staphylococci. However, its impact on the outcome is controversial. Conversely, rifampicin and/or fluoroquinolone resistance are associated with worse prognosis and might be considered when defining difficult-to-treat pathogens in the PJI setting. There is very little experience with recently developed anti-Gram-positive antimicrobial in PJI, but evaluations of their antibiofilm activities are promising, and some of them might represent significant advances regarding antimicrobial tolerance (such as tedizolid) or pharmacokinetic profiles (such as dalbavancin) during long-term treatment required for PJI. Evaluation of innovative strategies in this setting is crucial, including repositioning of current surgical options using local antimicrobial delivery, pharmacokinetic monitoring and modelling to optimize antimicrobial therapy, suppressive antimicrobial treatment and/or phage-based approaches. IMPLICATIONS: PJIs caused by resistant Gram-positive bacteria-including rifampicin- and/or fluoroquinolone-resistant staphylococci-may be associated with a poorer prognosis. It is therefore essential to optimize medical and surgical management, and to find new therapeutic alternatives.
引用
- Valour F, Miot O, Batailler C, et al. Management of Gram-positive multiresistant bacteria prosthetic joint infection: a narrative review on current and innovative strategies. Clin Microbiol Infect. 2025. PMID: 40294870. doi:10.1016/j.cmi.2025.04.021
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。